Duncan Walker

Duncan Walker is the Chief Development Officer at OnKure, Inc. He has a proven track record in cancer drug discovery and development, including contributing to the discovery and development of three FDA-approved medicines. Prior to joining OnKure, Dr. Walker was Head of Oncology at Kymera, and prior to that he worked at Forma Therapeutics, where he built and led the preclinical and early development group, and helped drive four novel small molecule drugs into and through Phase 1 studies over a five-year period. Dr. Walker was head of Translational Medicine and Development Project Lead at Array BioPharma, where he played key roles in the development and partnering of several molecules, including the MEK inhibitor binimetinib, and the Her2 inhibitor tucatinib. Earlier in his career, Dr. Walker held senior roles in several pharmaceutical and biotech companies, including Sunesis, Roche, and Glaxo. He did his postdoctoral training in the lab of Dr. Jim Maller at the University of Colorado and received a Ph.D. in Molecular Biology and Biochemistry from Washington University in St. Louis.